Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Idaho: below-average open trial sites
167 of 633 in-state trials are recruiting (26%); below the 37% national average by 11 percentage points.
According to ClinicalTrials.gov-derived indexes, Idaho sits in the lower half of US states by in-state trial count (#39 of 52 states by registered in-state trial count).
Idaho: 633 US clinical trials with in-state sites, 167 recruiting.
Idaho has 633 registered US clinical trials with a study site in-state, 167 of them currently recruiting (below the 37% national average by 11 percentage points). 246 of these trials are in Phase 3 (late-stage) and 197 in Phase 2. The most frequently studied condition in Idaho is Obesity, with 21 linked trials.
Thin-volume Idaho archive
Idaho open-enrollment share is 26% (p10 of states with sites; national baseline 37%). Treat this page as a compact local index (thin-volume · low-open), then jump to recruiting trials or methodology rather than expecting hub-scale coverage.
Below-average open enrollment
Idaho still shows 167 recruiting of 633 in-state trials (26% open), but below the 37% national average by 11 percentage points, so archived statuses weigh heavier than the national baseline.
- 26%
- open (below national share)
- 167
- still recruiting despite cool share
- 197
- Phase 2 rows in this footprint
- 21
- top: Obesity
Recruiting share is below the 37% national average by 11 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Idaho vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
633 Top 75% more indexed trials than 25% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for Idaho on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Idaho open-enrollment share sits below the national baseline.
167 of 633 in-state trials (26.4%) are recruiting, against 37% nationally (-10.6 percentage points). Counts include every study with at least one recorded site in the state.
-
Idaho trial sites spread across 8 city hubs.
Boise lists 305 of 633 in-state trials (48.2%) across 154 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Obesity is the most-studied condition in Idaho.
21 of 633 in-state trials (3.3%) list Obesity. That is a local concentration figure, not a national disease ranking.
-
Idaho sponsorship is fragmented across many organizations.
Eli Lilly and Company appears on 50 of 633 in-state trials (7.9%). Sponsor identity is as filed on ClinicalTrials.gov.
-
Most Idaho indexed trials have already finished enrollment.
328 of 633 (51.8%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 328 |
| Recruiting | 167 |
| Active | 138 |
By Phase
| Phase | Trial count |
|---|---|
| Phase 3 | 246 |
| Phase 2 | 197 |
| NA | 74 |
| Phase 4 | 34 |
| Phase 1 | 33 |
Top Conditions
Top Sponsors
Where trials run in Idaho
Boise carries 305 of Idaho's 633 indexed trials (48%) across 154 named sites, ahead of Idaho Falls at 151. 8 cities clear five listed trials, together naming 327 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Boise | 305 | 154 |
| Idaho Falls | 151 | 67 |
| Meridian | 88 | 40 |
| Coeur d'Alene | 72 | 31 |
| Post Falls | 36 | 14 |
| Nampa | 34 | 14 |
| Caldwell | 21 | 5 |
| Sandpoint | 18 | 2 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Open-share low
Idaho open-enrollment share is 26% (p10 of states with sites; national baseline 37%).
Idaho: open share sits in the low tercile of states
Sites spread across 8 cities with five or more listed trials, led by Boise (305, 48% of the state total) and Idaho Falls (151), together naming 327 distinct research locations.
Phase mix: 246 Phase 3 vs 197 Phase 2 (balanced across stages).
Top condition: Obesity (21 trials); top sponsor Eli Lilly and Company (50).
thin-volume · low-open figures (633 trials · 26% open) describe registry geography under the open-share low read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near Idaho on open-enrollment share
Cross-state peers under the open-share low read (thin-volume · low-open), not the same-state browse list.
Similar thin-volume peers (± open share)
- Delaware · 652 trials · 33% recruiting
- New Mexico · 579 trials · 29% recruiting
- Rhode Island · 753 trials · 34% recruiting
- New Hampshire · 471 trials · 33% recruiting
- Maine · 315 trials · 23% recruiting
Similar low-open peers (± trial volume)
- Nevada · 27% recruiting · 900 trials
- Hawaii · 26% recruiting · 437 trials
- Mississippi · 27% recruiting · 500 trials
- Alaska · 25% recruiting · 485 trials
- Louisiana · 28% recruiting · 1,936 trials